Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

Divi's Laboratories' Vizag unit gets USFDA EIR with 6 observations

Divi's Laboratories unit-II at Visakhapatnam was inspected by the USFDA in September, 2017 wherein a form-483 was issued with six observations.

November 18, 2017 / 04:03 PM IST

Drug firm Divi's Laboratories said it has received an establishment inspection report (EIR) from the US health regulator for its unit in Visakhapatnam.

Divi's Laboratories unit-II at Visakhapatnam was inspected by the USFDA in September, 2017 wherein a form-483 was issued with six observations.

"We have now received an Establishment Inspection Report (EIR) from US-FDA for our Unit-II, as closure of audit by FDA," the company said in a BSE filing.

The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA inspection when the agency determines the inspection to be closed.

first published: Nov 18, 2017 03:22 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347